Bdparib 200 Tablet

Introduction

Bdparib is a prescription medication that contains the active ingredient Rucaparib. It is available under the brand name Bdparib. This medication is primarily used for the treatment of certain types of ovarian cancer.

Uses

Bdparib is prescribed for the treatment of advanced ovarian cancer in adult patients who have received at least two prior lines of chemotherapy. It is specifically used for ovarian cancer that has a mutation in the BRCA gene and has responded to platinum-based chemotherapy.

Dosage and Administration

The dosage of Bdparib may vary depending on individual factors such as the patient’s weight, overall health, and response to treatment. Follow the instructions provided by your healthcare provider. Generally, the recommended dose is 600 mg taken orally twice daily, with or without food. The tablets should be swallowed whole and not crushed, chewed, or broken.

Mechanism of Action

Rucaparib, the active ingredient in Bdparib, belongs to a class of medications called PARP inhibitors. PARP inhibitors work by blocking an enzyme called poly (ADP-ribose) polymerase (PARP), which plays a role in repairing damaged DNA in cells. By inhibiting PARP, Rucaparib helps prevent cancer cells from repairing their DNA, leading to their death.

Side Effects

Common side effects may include nausea, vomiting, fatigue, loss of appetite, constipation, diarrhea, and abdominal pain. Notify your healthcare provider if these side effects persist or worsen.

Serious side effects of Bdparib may include low blood cell counts (anemia, neutropenia, and thrombocytopenia), which can increase the risk of infection, bleeding, and fatigue. Other serious side effects may include liver problems, lung problems, and allergic reactions. If you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

Bdparib may interact with other medications, including over-the-counter drugs, herbal supplements, and vitamins. Inform your healthcare provider about all the medications you are taking to avoid potential drug interactions. Some common drug interactions with Bdparib may include strong CYP3A inhibitors, such as ketoconazole and clarithromycin, which can increase the levels of Rucaparib in the body. Your healthcare provider will monitor you closely and may adjust your dose if necessary.

Precautions

Before starting Bdparib, inform your healthcare provider about any medical conditions you have, including liver or kidney problems. Disclose all the medications you are currently taking, as well as any allergies you may have.

Bdparib is not recommended for use during pregnancy. It may harm an unborn baby. Use effective contraception during treatment and for at least six months after the last dose of Bdparib.

Storage

Patient Tips

• Take Bdparib exactly as prescribed by your healthcare provider. Do not change your dose or stop taking the medication without consulting your doctor.
• attend all scheduled appointments with your healthcare provider for monitoring and blood tests.
• If you experience severe or persistent side effects, contact your healthcare provider immediately.
• Use effective contraception during treatment with Bdparib and for at least six months after stopping the medication, as it may cause harm to an unborn baby.
• Store the medication in a cool, dry place, away from direct sunlight and moisture.
• Do not share your medication with others, as it is prescribed specifically for your condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Rubraca 200 mg film-coated tablets (Health Professionals SmPC) Available at:
• Rucaparib (Drugs.com) [Accessed 5 Jun. 2024] (online) Available at:
• rucaparib tablet (RX) [Accessed 26 Jun. 2024] (online) Available at:
• Rucaparib (MedlinePlus) [Accessed 8 Jun. 2024] (online) Available at:
• Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. [Accessed 27 Jun. 2024] Available at: